Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of...
Covered in this story
What has happened since
- Syndax Pharmaceuticals Inc is up 0.3% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SNDX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Syndax Pharmaceuticals Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.